Description
Trestolone Acetate (MENT, 7α-Methyl-19-Nortestosterone Acetate) is a synthetic 19-nortestosterone derivative with additional 7α-methyl modification. The substance was developed by the Population Council in the 1990s as a potential male contraceptive - Phase II studies showed sperm suppression at low test levels.
Per study reports MENT binds with high affinity to the androgen receptor. The substance aromatizes to 7α-methyl-estradiol, bringing the classical estrogen protection effect but also enabling water retention and potential gynecomastia findings. The 7α-methyl group makes MENT resistant to 5α-reduction, reducing prostate effects.
An important property: MENT is about 10x more potent than testosterone as an anabolic substance. The contraceptive studies used 1-2mg/day transdermally to suppress sperm production with clinically normal test levels.
In recreational research practice MENT as acetate ester only acts briefly (half-life ~24 hours), requiring daily injections. This makes the compound impractical for standard cycles - most use is restricted to TRT research setups or short pre-contest phases.
Known effects in studies: strong HPG suppression (that was the contraceptive design goal), moderate aromatization, low 5α-reduction. The lipid profile worsens markedly under MENT in available studies.
Trestolone is on the WADA banned list.
You can order Trestolone Acetate as an oily injection solution in 10-pack at 50mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Trestolone Acetate is about ten times more potent than testosterone - the effects described in the literature are correspondingly pronounced. The strong HPG suppression was even the contraceptive design goal of the substance.
Documented in studies and the application literature:
- Strong HPG suppression: MENT was developed as a male contraceptive, the suppression of sperm production and endogenous testosterone production is documented in Phase II studies. Recovery after discontinuation is not guaranteed.
- Aromatization: MENT converts to 7-alpha-methyl-estradiol, with documented moderate estrogen effects including water retention and potential gynecomastia risk.
- Progestagenic component: as a 19-nor derivative there is a progestagenic residual action, as described for related Nandrolon compounds.
- Cardiovascular: in the available studies the lipid profile worsens markedly under MENT. The 7-alpha-methyl group reduces 5-alpha-reduction and thus prostate effects.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- 7alpha-Methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy - International Journal of Andrology 2000, Sundaram and Kumar: key review of MENT pharmacology as a male contraceptive and replacement candidate.
- 7alpha-Methyl-19-nortestosterone (MENT): the Population Council’s contribution to research on male contraception and treatment of hypogonadism - Contraception 2013: overview of the Population Council MENT research line including clinical data.
- Pharmacokinetics of 7alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men - Contraception 1999: pharmacokinetic study on MENT subdermal implants in humans.
- Prostate-Sparing Effects in Primates of the Potent Androgen 7-Methyl-19-Nortestosterone - Journal of Clinical Endocrinology and Metabolism 1998: primate study on MENT focusing on reduced prostate effects compared to testosterone.
- Biological properties of 17-ethinyl-7alpha-methyl-19-nortestosterone (U-13,851) - Contraception 1970: early characterization of the 7alpha-methyl-19-nor class from which the MENT line emerged.
